FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021109749> ?p ?o ?g. }

• W2021109749 endingPage "e59346" @default.
• W2021109749 startingPage "e59346" @default.
• W2021109749 abstract "Background Sub-Saharan Africa carries a high burden of co-infection with HIV-1 and hepatitis B virus (HBV). In this region, individuals with HIV-1/HBV co-infection on antiretroviral therapy (ART) frequently receive lamivudine as the only agent active against HBV, raising concerns for development of HBV resistance to lamivudine. We aimed to determine the prevalence, clinical, and virologic outcomes of chronic HBV infection, including HBV resistance to lamivudine, in a cohort of HIV-1 seropositive Kenyan women on long-term ART. Methods In this prospective cohort study, HIV-1 seropositive women initiated three-drug ART regimens that included lamivudine as the single drug active against HBV. Archived samples were tested for HBsAg, with further testing to determine HBeAg seroprevalence, HBV DNA suppression, and lamivudine resistance. We estimated the prevalence of chronic HBV and examined associations between HBV co-infection and clinical and virologic outcomes with chi-square tests, logistic regression, Kaplan-Meier and Cox regression. Results In a cohort of 159 women followed for a median of 3.4 years (interquartile range 1.4–4.5), 11 (6.9%; 95% CI 3.1–10.7) had chronic HBV infection. Of these, 9 (82%) achieved undetectable plasma HBV DNA levels. One woman developed lamivudine resistance, for an incidence of 3 per 100 person-years. The HBV co-infected women were at greater risk for abnormal ALT elevations compared to HIV-1 mono-infected women (HR 2.37; 95% CI 1.1–5.3). There were no differences between HBV-infected and uninfected women in mortality, CD4 count, or HIV-1 RNA suppression. Conclusion The prevalence of chronic HBV in this cohort was similar to recent studies from other African populations. Given our long-term follow-up, lamivudine resistance was lower than expected for HIV-1/HBV co-infected patients. Improved screening for HBV and extended follow-up of HIV-1/HBV co-infected individuals are needed to better understand the impact of different ART regimens on clinical outcomes in this population." @default.
• W2021109749 created "2016-06-24" @default.
• W2021109749 creator A5014597522 @default.
• W2021109749 creator A5021793610 @default.
• W2021109749 creator A5026703630 @default.
• W2021109749 creator A5029557883 @default.
• W2021109749 creator A5029877964 @default.
• W2021109749 creator A5030722040 @default.
• W2021109749 creator A5033799076 @default.
• W2021109749 creator A5060299759 @default.
• W2021109749 creator A5089969526 @default.
• W2021109749 creator A5090457174 @default.
• W2021109749 date "2013-03-18" @default.
• W2021109749 modified "2023-10-01" @default.
• W2021109749 title "Prevalence, Clinical and Virologic Outcomes of Hepatitis B Virus Co-Infection in HIV-1 Positive Kenyan Women on Antiretroviral Therapy" @default.
• W2021109749 cites W1964267496 @default.
• W2021109749 cites W1968461794 @default.
• W2021109749 cites W1988242030 @default.
• W2021109749 cites W2006265939 @default.
• W2021109749 cites W2014097029 @default.
• W2021109749 cites W2014610820 @default.
• W2021109749 cites W2029702357 @default.
• W2021109749 cites W2052966995 @default.
• W2021109749 cites W2057559835 @default.
• W2021109749 cites W2059622024 @default.
• W2021109749 cites W2065260112 @default.
• W2021109749 cites W2067318056 @default.
• W2021109749 cites W2067333579 @default.
• W2021109749 cites W2070341160 @default.
• W2021109749 cites W2080687168 @default.
• W2021109749 cites W2080941911 @default.
• W2021109749 cites W2086138999 @default.
• W2021109749 cites W2087564721 @default.
• W2021109749 cites W2087944742 @default.
• W2021109749 cites W2097504774 @default.
• W2021109749 cites W2098452591 @default.
• W2021109749 cites W2105571284 @default.
• W2021109749 cites W2109272165 @default.
• W2021109749 cites W2123767203 @default.
• W2021109749 cites W2134970942 @default.
• W2021109749 cites W2150925327 @default.
• W2021109749 cites W2157857312 @default.
• W2021109749 cites W2158274492 @default.
• W2021109749 cites W2161348345 @default.
• W2021109749 cites W2216475564 @default.
• W2021109749 cites W2314461521 @default.
• W2021109749 cites W2332787577 @default.
• W2021109749 cites W4247455741 @default.
• W2021109749 doi "https://doi.org/10.1371/journal.pone.0059346" @default.
• W2021109749 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3601052" @default.
• W2021109749 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23527168" @default.
• W2021109749 hasPublicationYear "2013" @default.
• W2021109749 type Work @default.
• W2021109749 sameAs 2021109749 @default.
• W2021109749 citedByCount "24" @default.
• W2021109749 countsByYear W20211097492014 @default.
• W2021109749 countsByYear W20211097492015 @default.
• W2021109749 countsByYear W20211097492016 @default.
• W2021109749 countsByYear W20211097492018 @default.
• W2021109749 countsByYear W20211097492019 @default.
• W2021109749 countsByYear W20211097492020 @default.
• W2021109749 countsByYear W20211097492021 @default.
• W2021109749 countsByYear W20211097492022 @default.
• W2021109749 countsByYear W20211097492023 @default.
• W2021109749 crossrefType "journal-article" @default.
• W2021109749 hasAuthorship W2021109749A5014597522 @default.
• W2021109749 hasAuthorship W2021109749A5021793610 @default.
• W2021109749 hasAuthorship W2021109749A5026703630 @default.
• W2021109749 hasAuthorship W2021109749A5029557883 @default.
• W2021109749 hasAuthorship W2021109749A5029877964 @default.
• W2021109749 hasAuthorship W2021109749A5030722040 @default.
• W2021109749 hasAuthorship W2021109749A5033799076 @default.
• W2021109749 hasAuthorship W2021109749A5060299759 @default.
• W2021109749 hasAuthorship W2021109749A5089969526 @default.
• W2021109749 hasAuthorship W2021109749A5090457174 @default.
• W2021109749 hasBestOaLocation W20211097491 @default.
• W2021109749 hasConcept C119060515 @default.
• W2021109749 hasConcept C126322002 @default.
• W2021109749 hasConcept C142462285 @default.
• W2021109749 hasConcept C159047783 @default.
• W2021109749 hasConcept C203014093 @default.
• W2021109749 hasConcept C2522874641 @default.
• W2021109749 hasConcept C2775940106 @default.
• W2021109749 hasConcept C2777382497 @default.
• W2021109749 hasConcept C2777410769 @default.
• W2021109749 hasConcept C2777813720 @default.
• W2021109749 hasConcept C2777869810 @default.
• W2021109749 hasConcept C2779889181 @default.
• W2021109749 hasConcept C2780593183 @default.
• W2021109749 hasConcept C71924100 @default.
• W2021109749 hasConcept C72563966 @default.
• W2021109749 hasConceptScore W2021109749C119060515 @default.
• W2021109749 hasConceptScore W2021109749C126322002 @default.
• W2021109749 hasConceptScore W2021109749C142462285 @default.
• W2021109749 hasConceptScore W2021109749C159047783 @default.
• W2021109749 hasConceptScore W2021109749C203014093 @default.
• W2021109749 hasConceptScore W2021109749C2522874641 @default.
• W2021109749 hasConceptScore W2021109749C2775940106 @default.

• next